Calcutta HC: Award May Be Set Aside if Tribunal Rewrites Contract or Ignores Key Clauses || Delhi HC Suspends Kuldeep Singh Sengar’s Life Term, Holding Section 5(C) of POCSO Not Made Out || Calcutta High Court: Arbitration Clause in an Expired Lease Cannot be Invoked For a Fresh Lease || Delhi High Court: 120-Day Timeline under Section 132B Of Income Tax Act is Not Mandatory || NCLAT Reaffirms That Borrower's Debt Acknowledgment Also Extends Limitation Period for Guarantors || NCLAT: Oppression & Mismanagement Petition Cannot Be Filed Without Company Membership on Filing Date || Supreme Court Quashes Rajasthan Village Renaming, Says Government Must Follow its Own Policy || NCLAT: NCLT Can Order Forensic Audit on its Own, No Separate Application Required || NCLAT Reiterates That IBC Cannot be Invoked as a Recovery Tool for Contractual Disputes || Delhi HC: DRI or Central Revenues Control Lab Presence in Delhi Alone Does Not Confer Jurisdiction

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :